The immunologic type of resistance of AML LSC is often associated with expression of immune checkpoint molecules, such as PD‐L1, CD47, TIM3, or other checkpoint molecules.75, 76, 77, 78, 79, 80, 81, 82. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.